ANG Lifesciences India Ltd
Incorporated in 2006, ANG Lifesciences India Ltd manufactures and markets finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials[1]
- Market Cap ₹ 34.9 Cr.
- Current Price ₹ 26.7
- High / Low ₹ 62.8 / 21.0
- Stock P/E
- Book Value ₹ 51.2
- Dividend Yield 0.00 %
- ROCE -4.12 %
- ROE -14.4 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.52 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -6.54% over past five years.
- Company has a low return on equity of -7.50% over last 3 years.
- Contingent liabilities of Rs.15.7 Cr.
- Promoters have pledged or encumbered 44.9% of their holding.
- Earnings include an other income of Rs.1.25 Cr.
- Company has high debtors of 264 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
34.50 | 36.84 | 54.92 | 66.93 | 75.13 | 121.27 | 126.08 | 154.24 | 348.52 | 206.82 | 131.30 | 89.91 | 98.27 | |
29.61 | 33.72 | 50.19 | 60.43 | 67.83 | 109.63 | 113.65 | 138.91 | 282.98 | 195.15 | 121.75 | 91.72 | 96.29 | |
Operating Profit | 4.89 | 3.12 | 4.73 | 6.50 | 7.30 | 11.64 | 12.43 | 15.33 | 65.54 | 11.67 | 9.55 | -1.81 | 1.98 |
OPM % | 14.17% | 8.47% | 8.61% | 9.71% | 9.72% | 9.60% | 9.86% | 9.94% | 18.81% | 5.64% | 7.27% | -2.01% | 2.01% |
0.12 | 0.09 | 0.21 | 0.25 | 0.69 | 0.23 | 0.42 | 0.75 | 0.95 | 9.84 | -0.89 | 2.44 | 1.25 | |
Interest | 1.51 | 1.66 | 1.66 | 1.77 | 1.85 | 2.64 | 3.22 | 3.98 | 8.31 | 10.92 | 9.77 | 7.30 | 7.24 |
Depreciation | 3.05 | 0.95 | 1.06 | 1.17 | 1.19 | 1.12 | 1.23 | 2.24 | 5.12 | 8.52 | 7.75 | 6.27 | 6.21 |
Profit before tax | 0.45 | 0.60 | 2.22 | 3.81 | 4.95 | 8.11 | 8.40 | 9.86 | 53.06 | 2.07 | -8.86 | -12.94 | -10.22 |
Tax % | 55.56% | 31.67% | 25.23% | 25.98% | 24.65% | 30.33% | 27.50% | 26.47% | 25.18% | 131.88% | -2.48% | -20.02% | |
0.19 | 0.40 | 1.65 | 2.82 | 3.72 | 5.65 | 6.10 | 7.25 | 39.71 | -0.66 | -8.65 | -10.34 | -8.37 | |
EPS in Rs | 0.21 | 0.43 | 1.79 | 3.07 | 2.86 | 4.35 | 4.69 | 5.58 | 30.55 | -0.51 | -6.62 | -7.92 | -6.41 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.61% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | -7% |
3 Years: | -36% |
TTM: | 1% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 28% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | -44% |
1 Year: | -45% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 9% |
3 Years: | -8% |
Last Year: | -14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3.68 | 3.68 | 3.68 | 3.68 | 5.18 | 5.18 | 5.18 | 5.18 | 10.37 | 13.06 | 13.06 | 13.06 |
Reserves | -0.97 | -0.57 | 1.09 | 3.81 | 17.99 | 23.58 | 29.37 | 36.17 | 73.11 | 72.48 | 64.01 | 53.75 |
11.03 | 10.15 | 11.77 | 14.01 | 17.42 | 21.90 | 20.83 | 42.40 | 60.99 | 55.56 | 59.36 | 70.57 | |
11.44 | 12.59 | 18.95 | 25.34 | 27.57 | 30.24 | 38.69 | 58.49 | 124.21 | 111.40 | 81.00 | 71.29 | |
Total Liabilities | 25.18 | 25.85 | 35.49 | 46.84 | 68.16 | 80.90 | 94.07 | 142.24 | 268.68 | 252.50 | 217.43 | 208.67 |
9.04 | 8.78 | 9.02 | 8.90 | 9.47 | 20.60 | 20.94 | 21.89 | 82.32 | 78.68 | 53.35 | 52.63 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.07 | 11.57 | 0.16 | 0.23 | 0.40 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 3.52 | 3.52 | 3.52 | 3.52 |
16.12 | 17.05 | 26.45 | 37.85 | 47.10 | 60.12 | 72.88 | 119.93 | 182.84 | 170.30 | 160.56 | 152.52 | |
Total Assets | 25.18 | 25.85 | 35.49 | 46.84 | 68.16 | 80.90 | 94.07 | 142.24 | 268.68 | 252.50 | 217.43 | 208.67 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
3.58 | 3.13 | 1.86 | 2.73 | 0.88 | 7.46 | 4.83 | -11.18 | 27.39 | 26.01 | -13.13 | -2.29 | |
-2.14 | -2.32 | -2.92 | -2.56 | -13.40 | -0.77 | -1.66 | -7.79 | -42.50 | -9.35 | 20.02 | -1.63 | |
-1.43 | -0.89 | 1.63 | -0.29 | 13.10 | -3.80 | -3.95 | 18.81 | 15.29 | -16.75 | -7.00 | 3.92 | |
Net Cash Flow | 0.02 | -0.08 | 0.56 | -0.12 | 0.57 | 2.89 | -0.77 | -0.16 | 0.17 | -0.08 | -0.12 | -0.01 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 79.67 | 62.22 | 108.86 | 139.39 | 156.19 | 125.66 | 133.34 | 139.10 | 103.67 | 137.85 | 192.56 | 263.71 |
Inventory Days | 83.99 | 84.14 | 46.81 | 44.62 | 53.41 | 27.18 | 41.03 | 67.62 | 46.29 | 92.90 | 143.34 | 227.95 |
Days Payable | 129.49 | 129.88 | 133.28 | 163.44 | 153.96 | 90.63 | 105.80 | 158.84 | 105.16 | 153.93 | 243.56 | 333.86 |
Cash Conversion Cycle | 34.17 | 16.48 | 22.39 | 20.58 | 55.64 | 62.21 | 68.56 | 47.88 | 44.80 | 76.83 | 92.34 | 157.81 |
Working Capital Days | 28.25 | 18.73 | 10.23 | 14.40 | 48.29 | 39.70 | 52.60 | 47.14 | 22.05 | 27.88 | 75.00 | 71.65 |
ROCE % | 13.65% | 16.74% | 26.04% | 29.34% | 21.90% | 23.56% | 21.92% | 19.90% | 53.78% | 8.51% | 1.78% | -4.12% |
Documents
Announcements
-
Standalone & Consolidated Unaudited Financial Results For The Quarter Ended 30.06.2025.
14 Aug - Q1 FY2025 unaudited financial results approved; reported losses; auditor's review unmodified.
-
Board Meeting Outcome for Board Meeting Outcome For Submission Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended June 30, 2025
14 Aug - Q1 FY2025 unaudited standalone and consolidated financial results approved; losses reported; auditor review unmodified.
-
Board Meeting Intimation for Conducting Board Meeting To Consider And Approve Unaudited Standalone & Consolidated Financial Results For The First Quarter Ended 30Th June, 2025.
6 Aug - Board meeting on 14 Aug 2025 to approve Q1 FY26 financial results; trading window closed from 1 July.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
16 Jul - Compliance certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30.06.2025.
-
Closure of Trading Window
21 Jun - Trading window closed from July 1, 2025 till 48 hours after Q1 June 30, 2025 results declaration.
Business Overview:[1][2]
Company manufactures and sells products like injections, tablets, capsules, syrups, ointments of different varieties. It deals in 4 market segments: institutional segment, third party manufacturing, direct marketing and export market. Apart from this, company is also providing printing & packing solutions especially in mono cartons, paper printing, corrugation, aluminiumfoils (blister foils)